Molecular imaging with Positron Emission Tomography (PET) is playing an important role in patient care, medical research, and pharmaceutical development. But limitations in short-lived positron emitters availability restrict the use of new radiopharmaceuticals that therefore remains limited to a small number of advanced research facilities. In order to enlarge the use of molecular imaging for translational research and clinical diagnosis, we designed an automated production system for PET radiopharmaceuticals on a “dose-on-demand” basis.
The LOTUS project is a French industry/academic partnership project, leaded by PMB (ALCEN Group), a designer and manufacturer of particle accelerators, RF assemblies, and advanced mechanical designs. The two other partners involved are the CEA, a technological research public organization, and SigmaPhi, a designer and producer of magnetic systems.
The LOTUS system features a compact 12 MeV superconducting Helium-free magnet cyclotron, with an external self-shielded beam and targetry system, particularly suitable for the production of Carbon-11, Fluor-18 and Gallium-68 radioisotopes. A microfluidic GMP automated synthesis platform allows the radiolabeling of a wide range of biomarkers for PET molecular imaging.